Skip to content

    Shilpa Medicare

    SHILPAMED
    Healthcare·6 Feb 2026
    Management Summary

    Shilpa Medicare delivered a strong Q3 FY26, reporting its highest ever quarterly revenue and EBITDA, driven by robust growth across API and Formulation segments. The company demonstrated significant margin expansion and improved ROCE, signaling successful monetization of past investments. Strategic progress was highlighted in CDMO, complex pipeline, and biologics, with several key projects nearing commercialization or advancing in clinical stages, despite some confidentiality constraints on specific product details.

    Highlights

    5
    • Reported highest ever quarterly revenue of ₹411 crores, recording a growth of 28% year-on-year.

    • Achieved highest ever quarterly EBITDA at ₹115 crores, reflecting a robust growth of 41% year-on-year.

    • EBITDA margins for the quarter were at a healthy 28%, up from 26% last year, driven by increased revenue and positive operating leverage.

    • 9-month PAT stood at ₹146 crores, nearly double the full year PAT of FY '25, indicating accelerated growth.

    • Adjusted ROCE (excluding Biologics and NBE investments) significantly improved from 3.5% in FY '23 to over 17% in the first 9 months period.

    Concerns

    3
    • An exceptional item of ₹13 crores pre-tax was incurred due to a change in Labour Code implemented by the Government of India.

    • Management declined to provide specific details on the scale and potential revenue of a US FDA-approved CDMO molecule due to confidentiality, limiting investor visibility.

    • Analyst noted a lack of substantial growth in non-captive API segment and questioned being late on certain oncology API filings, which management acknowledged as a 'very right observation'.

    Key financials

    Metrics

    8

    Periods

    2

    Headline

    4
    • Revenue
      ₹411 Cr
      YoY+28.0%
    • EBITDA
      ₹115 Cr
      YoY+41%
    • EBITDA Margin
      28%
      YoY+2%
    • PAT
      ₹55 Cr

    9M

    4
    • Revenue
      ₹1,110 Cr
      YoY+14.0%
    • EBITDA Margin
      29%
      YoY+3%
    • PAT
      ₹146 Cr
    • Adjusted ROCE
      17%

    Segment breakdown

    Non-captive API
    ₹186 Cr Revenue
    Captive API (including internal support)
    ₹243 Cr Revenue
    Formulation
    ₹177 Cr Revenue
    EU Formulation
    ₹73 Cr Revenue
    Formulation (ex-licensing)
    104% QoQ Growth83% 9M Growth
    List

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹87 crores

    internal accruals

    Debt

    Net ₹625 crores

    Guidance & targets

    29
    CategoryTargetPriority
    Capacity
    Dedicated commercial block for US NCE program commissioning
    Q4 FY '26
    High
    Capacity
    Large-scale peptide manufacturing capacity completion
    H2 FY '27
    High
    Capacity
    GMP facility for ADC manufacturing commissioning
    Q4 FY '26
    High
    Product Launch
    Third US NCE program exhibit batches
    Q1 FY '27
    High
    Product Launch
    Rotigotine (transdermal patch) launch
    FY '27
    High
    Product Launch
    Ondansetron long-acting injection commercialization (India)
    H1 FY '27
    High
    Product Launch
    New Formulation launches in Europe
    2
    High
    Product Development
    Oncology API validation batches completion
    Q4 FY '26
    High
    Product Development
    Peptide (Semaglutide) scale-up and validation batches completion
    Q4 FY '26 / Q1 FY '27
    High
    Product Development
    NorUDCA Europe human studies start
    Next financial year
    Medium
    Product Development
    Complex injectable registration batches completion
    Q4 FY '26
    High
    Product Development
    Ondansetron long-acting injection Europe clinical study
    Q4 FY '26
    High
    Product Development
    Ondansetron long-acting injection Europe Phase III completion
    FY '27
    High
    Product Development
    SMLTOP09 human clinical studies completion
    FY '27
    High
    Product Development
    SMLOSD014 clinical study start
    Q1 FY '27
    High
    Product Development
    New biosimilar products entering human studies
    2
    High
    Product Development
    SBPL01 (ADC product) human studies
    Next financial year
    High
    Product Development
    NBE (MABs) Phase I human studies
    FY '27
    High
    Product Development
    CDMO in biologics (Phase I studies)
    2 programs
    High
    Product Development
    Albumin India study completion
    End of FY '27 or Q1 FY '28
    Medium
    Product Filing
    Rotigotine (transdermal patch) US filing
    Q4 FY '26
    High
    Product Filing
    SMLOSD014 US filing
    H2 FY '27
    High
    Product Filing
    Aflibercept submission (India)
    H1 FY '27
    High
    Product Filing
    Albumin IMPD submission (Europe)
    Q4 FY '26
    High
    Commercialization
    Unicycive Therapeutics product commercialization
    FY '27
    High
    Volume
    API volume ramp-up
    Q2 next year
    Medium
    Market Expansion
    NorUDCA filing in all major RoW markets
    All major RoW markets
    High
    Revenue
    Licensing income run rate
    INR 150-odd crores
    Medium
    Partnerships
    Biologics partnerships
    Some partnerships
    High

    ADC GMP facility commissioning

    Q4 FY26
    CurrentUnder construction
    TargetCommissioned

    Why it matters

    This is the first ADC manufacturing facility in India and is crucial for the company's biologics CDMO strategy.

    GMP facility for our ADC manufacturing, we are planning to commission in Q4 FY '26.

    How to verify

    guidance_and_targets[metric='GMP facility for ADC manufacturing commissioning']

    Risks & concerns

    3
    RiskSeverity

    Confidentiality constraints on CDMO product details

    Management is bound by confidentiality agreements for partner products, limiting disclosure on potential revenue scale.Analyst acknowledged

    medium

    Pace of new oncology API product development

    Analyst noted the company being late on some oncology API filings, which management acknowledged as a 'very right observation' but indicated future filings.Analyst acknowledged

    medium

    Pending US FDA revert for Jadcherla facility

    The company has submitted CAPA responses following a US FDA inspection and is awaiting a revert.Management acknowledged

    medium

    Q&A highlights

    8

    “It is our partner's product, and we are bounded by confidentiality.”

    Management's inability to disclose details on a potentially significant product limits investor's ability to assess its future revenue impact.

    asked by Shubham Sehgal

    2 min read5 chapters

    Detailed Narrative

    01

    Robust Q3 FY26 Financial Performance

    Shilpa Medicare reported its highest ever quarterly revenue of ₹411 crores, marking a 28% year-on-year growth. EBITDA also reached a record ₹115 crores, up 41% YoY, with EBITDA margins expanding to a healthy 28% from 26% in the prior year. For the nine-month period, revenue stood at ₹1,110 crores (up 14% YoY) and PAT reached ₹146 crores, nearly doubling the full year PAT of FY25. The company's adjusted Return on Capital Employed (ROCE) significantly improved from 3.5% in FY23 to over 17% in 9M FY26, reflecting effective asset utilization.

    02

    Strategic Advancements in API Business

    The API segment saw the addition of three new CDMO programs, with one NCE program for a US customer already commercialized. Another US NCE program, partnered with Unicycive Therapeutics, will see its dedicated commercial block commissioned in Q4 FY26, with exhibit batches in Q1 FY27. The company also added 10 new oncology products to its pipeline, validating three this quarter, and plans to complete validation batches for one non-infringing oncology API in Q4 FY26. A new peptide manufacturing capacity, with an investment of ₹40 crores, is underway and expected to be completed in H2 FY27, focusing on GLP-1 products like Semaglutide and Liraglutide.

    03

    Formulation Business Gains Traction

    The newly launched NCE molecule, NorUDCA, has exceeded expectations with a strong order book for Q4 FY26, and plans are in place to initiate human studies for Europe next financial year. The existing commercial 505(b)(2) products are showing healthy sequential growth, with EU Nilotinib volumes demonstrating strong traction. The company received marketing authorization for its first transdermal patch product, Rotigotine, which is slated for launch in Q1 FY27, with US filing planned for Q4 FY26. The Formulation business (excluding licensing income) grew 104% QoQ and 83% for the 9-month period.

    04

    Progress in Complex Pipeline and Biologics

    The complex pipeline is advancing, with Ondansetron long-acting injection having completed Phase III studies and filed in India, targeting commercialization in H1 FY27. European clinical studies for Ondansetron are planned for Q4 FY26. In Biologics, Phase III studies for Aflibercept are progressing in India, targeting submission in H1 FY27. The company's first ADC product, SBPL01, has completed lab development and will enter human studies next financial year. A GMP facility for ADC manufacturing is scheduled for commissioning in Q4 FY26, marking a significant milestone as the first of its kind in India.

    05

    Capital Allocation Focused on Growth and Efficiency

    The company incurred a capex of ₹87 crores in Q3 FY26, primarily funded through internal accruals. Net debt stood at ₹625 crores as of December 31, 2025, with a debt-to-equity ratio of approximately 0.25-0.26. Management expressed confidence in funding future capex from internal accruals and maintaining debt levels, indicating a focus on improving operating leverage and ROCE. The strategic investments made over recent years are now expected to yield maximum returns through execution and scaling.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.